How Common Is Lymphedema Worldwide?

Lymphedema affects millions of people worldwide, yet its prevalence appears very different from one country to another. These differences are often misunderstood. They do not mean that lymphedema is rare in some regions and common in others. Rather, they reflect how healthcare systems identify, record, and manage the condition.

Understanding these global differences is essential for improving diagnosis, expanding access to care, and supporting long-term management strategies such as compression therapy.

Global lymphedema prevalence: what do we actually know?

There is no single global registry for lymphedema. However, based on large reviews and public health data, global estimates commonly range between 140 and 250 million people.

This wide range reflects several factors, including underdiagnosis, inconsistent diagnostic criteria, and limited reporting in many regions.

Lymphedema includes both primary lymphedema, which is congenital or hereditary, and secondary lymphedema, which may develop after cancer treatment, infection, trauma, chronic venous disease, or surgery.

In many parts of the world, lymphedema is still diagnosed late, often after swelling becomes irreversible, despite evidence that early intervention and compression therapy can significantly slow disease progression.

Why lymphedema numbers differ by country?

Awareness and diagnosis

Countries with established clinical guidelines, trained therapists, and clear referral pathways tend to diagnose more patients earlier. In regions with lower awareness, lymphedema is often described simply as “swelling” or attributed to weight, aging, or venous disease.

Access to treatment

Availability of compression garments, pneumatic compression devices, and ongoing follow-up care strongly influences whether patients are formally diagnosed and recorded within healthcare systems.

Reporting systems

Some countries track lymphedema through cancer registries, vascular clinics, or specialized services. Others do not track it systematically at all, which can make prevalence appear artificially low.

Examples from different regions

Figures reflect best available published estimates or prevalence ranges and are not directly comparable between countries.

United States

An estimated 8 to 10 million people are living with lymphedema. Most cases are secondary, commonly following cancer treatment. Breast cancer–related lymphedema alone affects approximately 15 to 30 percent of survivors, depending on treatment type and measurement method. Compression therapy is widely recognized as a cornerstone of long-term management.

United Kingdom

More than 200,000 people are estimated to be affected. Prevalence increases with age and comorbidities, and many cases are managed in community care settings, suggesting additional underdiagnosis.

Germany

Population-based studies suggest a prevalence of approximately 1.5 to 2 percent. Higher reported numbers reflect strong outpatient lymphatic and vascular care systems, where early use of compression therapy supports better long-term outcomes.

France

Estimated prevalence ranges between 1 and 2 percent. Secondary lymphedema related to oncology and venous disease is common, and long-term compression management plays a central role in care pathways.

India

India carries the world’s largest burden related to lymphatic filariasis. Hundreds of millions of people live in regions that have historically been at risk. Official data reports hundreds of thousands of diagnosed cases, but the true prevalence is believed to be significantly higher. Limited access to long-term compression therapy remains a major challenge in many areas.

Sub-Saharan Africa

Prevalence varies widely by country. Infection-related lymphedema remains common in some regions, particularly in rural areas. Late diagnosis and limited access to long-term compression solutions contribute to disease progression.

Southeast Asia

Several countries continue to report a significant lymphedema burden related to infection, surgery, and cancer treatment. National statistics often reflect only advanced or treated cases.

Why higher numbers often mean better care?

Countries that report higher lymphedema prevalence typically have better diagnostic awareness, trained clinicians and therapists, reimbursement or access to compression therapy, and structured follow-up systems.

In this context, higher prevalence often reflects better detection and reporting rather than worse population health.

The role of compression therapy worldwide

Across all regions, one principle remains consistent: lymphedema requires long-term management.

Evidence-based compression therapy, including compression garments and pneumatic compression systems, plays a key role in supporting lymphatic and venous flow, reducing swelling, helping prevent progression and complications, and improving daily function and quality of life.

Early and consistent use of compression therapy can significantly change the trajectory of the condition, regardless of geography.

A global condition, a shared responsibility

Lymphedema is not rare, local, or limited to specific populations. It is a global, chronic condition that benefits from early recognition, patient education, and access to appropriate compression therapy.

Improving awareness and access worldwide is essential to closing gaps in care and supporting people living with lymphedema wherever they are.